Onesource Specialty Pharma has informed that Board of Directors of the Company, in their meeting held today i.e., on Wednesday, May 13, 2026, have approved the following: 1. Audited Financial Results (Standalone and Consolidated) of the Company for quarter and year ended March 31, 2026. In this regard, it has enclosed: (i) A copy of the Audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 2026, along with Auditors’ Report; and (ii) Declaration of unmodified opinion in the Auditors’ Report for the financial year ended March 31, 2026 enclosed herewith as Annexure A; Appointment of B S R & Co LLP, Chartered Accountants (Firm’s Registration No.:101248W/W-100022), as the statutory auditors of the Company to hold office from the conclusion of the 19th Annual General Meeting for a term of five consecutive years, i.e., until the conclusion of the 24th Annual General Meeting, in place of Deloitte Haskins & Sells, Chartered Accountants (Firm Registration No. 008072S), whose term is ending on the ensuing annual general meeting. Disclosure pursuant to Regulation 30 of the SEBI Listing Regulations., read with SEBI Master Circular No. O/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, enclosed as Annexure B.
The above information is a part of company’s filings submitted to BSE.
